IN THE SPOTLIGHT

Another LAP in the Race
Sylvia M. Lee1,2 and Cassian Yee1,2

Summary: The unique promise of latency-associated peptide resides in its selective presence on regulatory T cell (Treg) in the activated setting after patients are treated with immunomodulators such as anti–CTLA-4. The improved ability to track, scrutinize, and potentially target Tregs in this manipulated environment will be increasingly critical in developing immune-based therapies for patients with cancer. Cancer Discovery. 2(2):107–9. © 2012 AACR.

Commentary on Sun et al., p. 122(7).

The identification of regulatory T cells (Treg), long thought to be mythical objects of immunologic hand-waving, led to a greater appreciation for the ability of the immune response and the mechanisms responsible for initiating and tempering a cell-mediated response to pathogens, autoantigens, and tumor cells. From the start, however, there have always been limitations to the markers that were used to identify such Tregs.

In 1995, the laboratory of Sakaguchi first described a population of CD4+ T cells constitutively expressing elevated levels of CD25 on the surface that exhibited immunosuppressive properties (1). Expression of FoxP3 was later linked to this hallmark feature of Tregs—suppression of a proliferative or functional lymphocyte response—and subsequently became the phenotypic gold standard for a Treg (2).

In the last decade, Tregs were found to play a prominent role in tumor immunity and immune escape; not only was an increased frequency of Tregs in peripheral blood and at tumor sites associated with disease stage and progression in patients with cancer (3, 4), but the ratio of Tregs to other effector cells appeared to hold prognostic significance (5). In addition, it was demonstrated that the depletion of Tregs could induce tumor eradication in animal models (6).

Thus, the race goes on to characterize Tregs, to elucidate their mechanisms and relationships with other cells, and to understand what factors control their expansion and contraction. However, the ability to study Tregs in a more precise and nondestructive fashion has been hampered by the specificity (or lack thereof) of known markers. Although high surface CD25 expression is commonly used to identify Tregs, recent activation of effector T cells can lead to upregulation of CD25 as well, confounding the identification of true Tregs in vitro and in vivo. The most widely accepted marker for Tregs, FoxP3, is found intracellularly; therefore, fixation and permeabilization are required to detect expression, limiting the ability to isolate viable T cells for downstream studies or to target Tregs using surface ligands (Fig. 1).

Other surface markers, such as CD127, which is found to be decreased or absent among CD4+CD25hi T cells, have recently been used to attain a more refined population of Tregs. However, as Sun and colleagues (7) demonstrate in their article in this issue of Cancer Discovery, this combination also fails to adequately distinguish a functionally suppressive Treg population from conventional effector T cells in the activated setting.

In vitro activation of effector CD4 T cells leads to a CD127−/−, CD25hi phenotype not dissimilar from the natural Treg, thus confounding nondestructive identification of Tregs. With the advent of cell-cycle checkpoint inhibitors to the clinical arena, such as the recently approved anti–CTLA-4 antibody ipilimumab, the intrinsic CTLA-4 brake on T-cell proliferation can be released after T-cell receptor engagement, leading to sustained activation and unchecked proliferation of effector T cell; for tumor immunologists, this is a desirable perturbation leading to enhancement of the endogenous T-cell responses to tumor-associated antigens. However, global activation leads to upregulation of CD25 and lowered CD127 levels among activated effectors, recapitulating a similar phenotype observed after in vitro activation. Thus, distinguishing these “beneficial” antitumor effectors from the population of Tregs on the basis of CD25 and CD127 expression in this setting can be problematic.

In recent years, there has been growing interest in the role of latency-associated peptide (LAP) and its presence on the surface of a subset of Tregs. LAP binds and forms a latent complex with TGF-β, one of the principal cytokines by which Tregs are thought to suppress immune responses. In 2008, Chen and colleagues (8) described a unique population of CD4+CD25hi LAP+ Tregs that demonstrated more potent suppressive activity that was TGF-β dependent compared with CD4+CD25hi LAP− Tregs. LAP also was identified by Tran and colleagues (9) to be a new marker that could help distinguish activated Tregs from activated FoxP3+ and FoxP3− T effectors.

In this issue of Cancer Discovery, Sun and colleagues (7) demonstrate that although CD25hi, CD127− is a good marker for unactivated Tregs both phenotypically (correlation with FoxP3) and functionally (maintenance of suppressive
capacity), the same cannot be said for healthy donor peripheral blood mononuclear cells after in vitro activation, where more than two thirds of such CD25hi, CD127lo cells lacked suppressive capacity. The group, however, was able to demonstrate a positive correlation with FoxP3 expression and functional suppression among the population of LAP+ cells, which had increased in frequency from 0.3% to 12% after in vitro activation.

Along similar but even more compelling lines, when samples were collected from patients after anti–CTLA-4 therapy, CD4+CD25+CD127lo cells from posttherapy samples were incapable of suppressing lymphocyte proliferation, whereas CD4+CD25+LAP+ T cells were functionally suppressive. Therefore, LAP positivity more accurately reflects the Treg population among patients receiving anti–CTLA-4 therapy, and potentially, patients treated with other immunomodulatory-based therapies as well, such as inhibitors of the PD1/PDL-1 axis checkpoint (10).

For anti–CTLA-4 and likely for other immune-based strategies in which the clinical response is often delayed for weeks or months, sometimes worsening before improving, the identification of a predictive marker would be a valuable clinical tool (11). This new era of ipilimumab and its novel response patterns has presented oncologists with unfamiliar treatment dilemmas in which they are forced to decide, with very little radiographic guidance and in the face of possible autoimmune toxicities, whether to discontinue potentially promising therapy. The use of LAP alone or in combination with other markers (e.g., inducible costimulator; refs. 12, 13), may allow the formulation of a predictive algorithm to aid in clinical decision-making.

The greater precision afforded by LAP in selecting Tregs may also provide a new strategy for Treg depletion. In vivo depletion of Tregs by the use of agents such as denileukin diftitox (interleukin-2–conjugated diphtheria toxin) or daclizumab (anti-CD25 Ab) that target CD25 expression have led to occasional successes (14) but sometimes inconsistent results (15, 16). The development of novel targeted agents against LAP could provide a more effective means of achieving Treg depletion, albeit with a potential new set of toxicities from the on-target damage to LAP+ megakaryocytes, platelets, and immature dendritic cells.

As the early success of checkpoint inhibitors ignites an explosion of research into additional applications and combination strategies (e.g., PD1/PDL1, ipilimumab in conjunction with vaccines, ipilimumab, and BRAF inhibition), the ability to accurately track Tregs in these manipulated environments will become increasingly important. Sun and colleagues (7) make the additional point that LAP and FoxP3 expression are not perfectly concordant on CD4+CD25+ T cells (i.e., there are T cells that are LAP+ but FoxP3− and other T cells that are LAP− but FoxP3+). With growing evidence that points to the remarkable heterogeneity of Tregs, it remains to be seen how LAP expression will play out in the future delineation of Treg subpopulations, including the more recently discovered CD8+ Tregs. Ongoing efforts by this group and others to identify and characterize Treg subsets, and to identify reliable markers for following Tregs under clinically relevant conditions, will keep us on track to developing more effective immunotherapies.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Received January 9, 2012; accepted January 9, 2012; published online February 13, 2012.

REFERENCES

9. Tran DQ, Andersson J, Hardwick D, Bebris L, Illie GG, Shevach EM. Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures. Blood 2009;113:5125–33.
Another LAP in the Race
Sylvia M. Lee and Cassian Yee


Updated version  Access the most recent version of this article at:
http://cancerdiscovery.aacrjournals.org/content/2/2/107

Cited articles  This article cites 16 articles, 12 of which you can access for free at:
http://cancerdiscovery.aacrjournals.org/content/2/2/107.full.html#ref-list-1

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.